HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human
¥3000 | |
Z06598-100 | |
|
|
|
|
|
¥3000 | |
Z06598-100 | |
|
|
|
|
|
Species | Human | ||||||
Protein Construction |
|
||||||
Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||||
Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human at 2μg/ml (100μl/well) on the plate can bind AntiHLAA*02:01&B2M&WT1 (RMFPNAPYL) Antibody, hFc Tag. Test result was comparable to standard batch | ||||||
Expression System | HEK293 | ||||||
Theoretical Molecular Weight | 50.5 kDa | ||||||
Apparent Molecular Weight | Due to glycosylation, the protein migrates to 52-60 kDa based on Bis-Tris PAGE result. | ||||||
Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&WT-1 Antibody, hFc Tag with the EC50 of 11.2 ng/ml determined by ELISA. »
The purity of HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human was greater than 95% as determined by SEC-HPLC. »
HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human, His Tag captured on CM5 Chip via Anti-His Antibody can bind Anti-HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Antibody, hFc Tag with an affinity constant of 0.33nM as determined in SPR assay (Biacore T200). »
Target Background | The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1. |
Synonyms | MHC; WT1; RMF; AWT1; GUD; NPHS4GUD; WAGR; WIT-2; WT33 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.